Acurx Pharmaceuticals

Boustead Securities

Acurx Pharmaceuticals, LLC

www.acurxpharma.com

Acurx Pharmaceuticals, LLC is a privately held clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC) and Food and Drug Administration (FDA). Priority pathogens are those which require new antibiotics to address the worldwide crisis of antimicrobial resistance, or AMR, as identified by the WHO, CDC and FDA. The CDC estimates that someone in the U.S. gets an antibiotic resistant infection every 11 seconds and every 15 minutes someone dies. According to the WHO, the clinical development pipeline remains insufficient to tackle the challenge of increasing emergence and spread of antimicrobial resistance.[1,2]

1. Centers for Disease Control, November 2019
2. World Health Organization, December 2019

Market Overview

2018 Global Antibiotic Industry **$45.31b[1]**	Expected Antibiotic CAGR **~4%[2]**
2018 U.S. Pharmaceutical Industry **$485b[3]**	Expected Pharmaceutical CAGR **~4%-5%[4]**
2018 Global Pharmaceutical Industry **$1.2t[5]**	

1-2. Research and Markets, Feb 2019.
3-5. Biospace, Feb 2019.

Business Model

We are developing a new class of antibiotics targeting difficult-to-treat and resistant bacteria known as DNA polymerase IIIC Inhibitors (Pol IIIC). Pol IIIC is an enzyme required for the replication of DNA in certain bacterial cells. By blocking the enzyme, our antibiotic candidates may be able to kill bacterial cells, including resistant bacteria such as *C. difficile*, methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE) and other resistant bacteria. We intend to "de-risk" the class through our drug development activities and then partner with a fully integrated pharmaceutical company for late stage trials and commercialization.

Mechanism of Action



Ibezapolstat is first-in-class DNA inhibitor of polymerase IIIC, the enzyme known to be the primary catalyst for the replication of DNA in certain bacterial cells. Two most commonly used treatments for CDI work by inhibiting synthesis of RNA or cell walls. We believe Ibezapolstat is one of the first antibiotics in clinical trials to work by inhibiting the enzyme necessary for DNA replication of the bacterial cell. Our product pipeline is based on the same mechanism of action which has already achieved proof of concept in animal studies for CDI.

OFFERING TERMS SUMMARY	
MINIMUM AMOUNT	$3,000,000
MAXIMUM AMOUNT	$10,000,000
TYPE	Class A Interest
PRICE	$4.00 per Class A Interest
USE OF PROCEEDS	Pre-Clinical Development, Clinical Trials, Patents Working Capital

Peter Conley
Managing Director, Head of IP Banking
Boustead Securities, LLC
Pete@boustead1828.com
310-383-7874